• Je něco špatně v tomto záznamu ?

Interactions of beta-blockers with model lipid membranes: molecular view of the interaction of acebutolol, oxprenolol, and propranolol with phosphatidylcholine vesicles by time-dependent fluorescence shift and molecular dynamics simulations

G. Först, L. Cwiklik, P. Jurkiewicz, R. Schubert, M. Hof,

. 2014 ; 87 (3) : 559-69.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014439

Since pharmacokinetic and pharmacodynamic activities of drugs are often related to their interactions with biomembranes, it is of high interest to establish an approach for the characterization of these interactions at the molecular level. For the present study, beta-blockers (oxprenolol, propranolol, and acebutolol) were selected due to their well described nonspecific membrane effects (NME). Their interactions with model lipid membranes composed of palmitoyloleoylphosphatidylcholine (POPC) were studied using Time-Dependent Fluorescence Shift (TDFS) and Generalized Polarization (GP) as well as molecular dynamics (MD) simulations. Liposomal vesicles were labeled with fluorescent membrane polarity probes (Laurdan, Prodan, and Dtmac). Increasing beta-blocker concentrations (0-10 mM for acebutolol and oxprenolol, and 0-1.5 mM for propranolol) significantly rigidifies the lipid bilayer at the glycerol and headgroup level, which was detected in the steady-state and in the time-resolved fluorescence data. The effects of propranolol were considerably stronger than those of the two other beta-blockers. The addition of fluorescent probes precisely located at different levels within the lipid bilayer revealed the insertion of the beta-blockers into the POPC bilayer at the glycerol backbone level, which was further confirmed by MD simulations in the case of propranolol.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014439
003      
CZ-PrNML
005      
20150427101902.0
007      
ta
008      
150420s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpb.2014.03.013 $2 doi
035    __
$a (PubMed)24681296
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Först, Gesche $u Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, University of Freiburg, Freiburg, Germany. Electronic address: gesche@foerst.de.
245    10
$a Interactions of beta-blockers with model lipid membranes: molecular view of the interaction of acebutolol, oxprenolol, and propranolol with phosphatidylcholine vesicles by time-dependent fluorescence shift and molecular dynamics simulations / $c G. Först, L. Cwiklik, P. Jurkiewicz, R. Schubert, M. Hof,
520    9_
$a Since pharmacokinetic and pharmacodynamic activities of drugs are often related to their interactions with biomembranes, it is of high interest to establish an approach for the characterization of these interactions at the molecular level. For the present study, beta-blockers (oxprenolol, propranolol, and acebutolol) were selected due to their well described nonspecific membrane effects (NME). Their interactions with model lipid membranes composed of palmitoyloleoylphosphatidylcholine (POPC) were studied using Time-Dependent Fluorescence Shift (TDFS) and Generalized Polarization (GP) as well as molecular dynamics (MD) simulations. Liposomal vesicles were labeled with fluorescent membrane polarity probes (Laurdan, Prodan, and Dtmac). Increasing beta-blocker concentrations (0-10 mM for acebutolol and oxprenolol, and 0-1.5 mM for propranolol) significantly rigidifies the lipid bilayer at the glycerol and headgroup level, which was detected in the steady-state and in the time-resolved fluorescence data. The effects of propranolol were considerably stronger than those of the two other beta-blockers. The addition of fluorescent probes precisely located at different levels within the lipid bilayer revealed the insertion of the beta-blockers into the POPC bilayer at the glycerol backbone level, which was further confirmed by MD simulations in the case of propranolol.
650    _2
$a acebutolol $x metabolismus $7 D000070
650    _2
$a beta blokátory $x metabolismus $7 D000319
650    _2
$a fluorescence $7 D005453
650    _2
$a fluorescenční barviva $x metabolismus $7 D005456
650    _2
$a glycerol $x metabolismus $7 D005990
650    _2
$a lipidové dvojvrstvy $x metabolismus $7 D008051
650    _2
$a liposomy $x metabolismus $7 D008081
650    _2
$a membránové lipidy $x metabolismus $7 D008563
650    _2
$a simulace molekulární dynamiky $7 D056004
650    _2
$a oxprenolol $x metabolismus $7 D010096
650    _2
$a fosfatidylcholiny $x metabolismus $7 D010713
650    _2
$a propranolol $x metabolismus $7 D011433
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cwiklik, Lukasz $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, v. v. i., Prague 8, Czech Republic. Electronic address: lukasz.cwiklik@jh-inst.cas.cz.
700    1_
$a Jurkiewicz, Piotr $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, v. v. i., Prague 8, Czech Republic. Electronic address: piotr.jurkiewicz@jh-inst.cas.cz.
700    1_
$a Schubert, Rolf $u Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, University of Freiburg, Freiburg, Germany. Electronic address: rolf.schubert@pharmazie.uni-freiburg.de.
700    1_
$a Hof, Martin $u J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, v. v. i., Prague 8, Czech Republic. Electronic address: martin.hof@jh-inst.cas.cz.
773    0_
$w MED00001640 $t European journal of pharmaceutics and biopharmaceutics official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 87, č. 3 (2014), s. 559-69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24681296 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150427102206 $b ABA008
999    __
$a ok $b bmc $g 1072020 $s 897317
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 87 $c 3 $d 559-69 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...